

Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients

Marcus Inyama Asuquo^{1,2,*}, Emmanuel Effa^{1,2}, Akaninyene Otu^{1,2,3}, Okokon Ita¹, Ubong Udoh¹, Victor Umoh^{2,4}, Oluwabukola Gbotosho⁵, Anthonia Ikpeme^{1,2}, Soter Ameh⁶, William Egbe^{1,2}, Margaret Etok², Jochen Guck⁷, Andrew Ekpenyong^{2,8}

¹Faculty of Medicine, College of Medical Sciences, University of Calabar, Calabar, Nigeria

²Joseph Ukpo Hospitals and Research Institutes (JUHRI), Afua Site, Ibiono Ibom, Nigeria

³Department of Infection and Travel Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK

⁴Department of Internal Medicine, College of Health Sciences, University of Uyo, Uyo, Nigeria

⁵Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA

⁶Biostatistics Unit, Department of Community Medicine, University of Calabar, Calabar, Nigeria

⁷Max-Planck-Zentrum für Physik und Medizin, Staudtstr. 2, 91058 Erlangen, Germany

⁸Department of Physics, Creighton University, Omaha, NE, 68178, USA

*Corresponding author. Email: markaniekan@gmail.com.

Keywords: COVID-19, antibody, serological testing, SARS-CoV-2.

Supplementary Information (SI)

Supplementary Information I: Consent Form

Study Title:

Antibodies Testing for SARS-CoV-2 Exposure in Akwa Ibom and Cross River States of Nigeria: a Seroepidemiologic Study to Guide Responses to COVID-19 Pandemic

Name and roles of investigators

Dr. Marcus Inyama ,

UCTH Site;

Dr. Victor Umoh,

JUHRI Afua and UUTH Uyo

Part A. Participant Information

What is the purpose of this study?

Many people have been exposed to corona virus without being aware. They are said to be asymptomatic. Such people after some time will develop immunity or antibodies against the virus. It is easy to test for the antibodies against the virus than conduct diagnostic test to detect the virus in our bodies. This research is aimed at determining how many people have been exposed to the virus by detecting the antibodies in their blood. This information can have very useful purpose in making decisions that will help the community as a whole.

Why have you been asked to participate in this study?

You are being requested to participate in this research as a member of the community who may have been exposed to people who have the potential of carrying the virus without knowing. This can be due to the nature of work which exposes us to so many people a day thereby increasing the risk of having come in contact with a potential carrier of the virus. If this is so, and you are still healthy, it is very likely your body had developed sufficient immunity to protect you. This is done by the development of antibodies against the virus. We are out to carry out this test to determine how many people in have developed these antibodies.

What does taking part in this study involve?

We will ask you to provide answers to a questionnaire that includes questions about yourself, your health, family health history and treatment-related information that is important to this research. We will collect this information on paper. The research assistant will be there to provide the necessary assistance. We will use a small instrument to collect approximately 5µl of blood from your finger after you have given consent to participate in this study. We will analyze the blood to see the level of exposure to this disease.

Expected duration of research

We expect your participation will take about 25 minutes and we will have only one encounter with you. However, we may re-contact you in future for further information if you approve.

What are the possible risks/discomforts involved in the study?

The most common risks related to finger prick is the initial pain you will experience. Sometimes there is infection at the site of needle prick, but this is rare. Despite all our efforts, unanticipated situations, such as unauthorized access to a computer may occur and someone could get access to the data, we have stored about you. We believe the chance that these will happen is very small.

What are the potential benefits involved in the study?

The direct benefit for you, should you agree to participate in this study, is that we will provide the materials needed for any sample collection as part of your participation in this research.

Other benefits of this study are that the data gathered and analyzed, may be useful in developing new approaches to controlling this novel disease and preventing spread without adversely affecting your comfort.

Will the information we collect be kept private?

The results of this study will be kept strictly confidential and used mainly for research purposes and the development of a research report. Your name will not appear anywhere on the research findings. Paper records will be kept locked in a secure research office and any electronic documents will be stored securely and only accessed by the research team. Study records that identify you will be kept confidential.

What will happen to my data or samples after the study?

As part of this study, we will store some of the blood/tissue specimens collected from you. The specimens will be destroyed immediately after testing.

What are the costs to your participation?

Participating in this study will not have any direct cost to you except for your time.

Will there be any compensation?

The answer to that question is NO

What are your rights in this study?

Participation in this study is entirely voluntary. You have the choice to choose to participate or not to take part at all. Your medical care at this hospital will not be affected if you choose not to participate. Even if you decide to participate, you can quit at any time.

Alternatives to Participation

Your alternative is not to participate in this study and continue to receive normal care.

How will I know about the results from this study?

When this study is completed, we will share the findings with the participating sites and other researchers in Nigeria and internationally. The reports will be written in a way that none of the participants can be identified. The study investigators at each study site will organize meetings at the clinics to inform people of the findings from this study. In general, individual results of tests conducted in this study will not be shared with you or put in your medical records. However, if we find anything that is important for your health, we will contact your doctors to see how they can use that information to improve your care.

Who can you contact for questions or problem?

This study is led by a principal investigator at each site. If you have questions or concerns regarding this study, you can contact your site's Principal Investigator (Name of Site PI) at:

1. Joseph Ukpo Hospitals & Research Institutes (JUHRI), Afua, Akwa Ibom State
Principal Investigator: Dr Victor Umoh: Phone e-mail.
2. University of Uyo Teaching Hospital, Uyo, Akwa Ibom.
Principal Investigator: Dr Victor Umoh : Phone e-mail.
3. University of Calabar Teaching Hospital.
Principal Investigator: Dr Marcus Inyama

To protect your interests, all studies conducted at each site are looked at by an independent group of people called a Research Ethics Committee. This study has been reviewed and has been approved by [UCTH HEALTH] Research Ethics Committee. If you have any questions regarding your rights, or feel that your rights as a participant have been violated, the Chairman can be contacted at the following address:

Prof John Ekabua,
Chairman, UCTH HREC,
University of Calabar Teaching Hospital
07035203645
johnekabua@outlook.com

In addition, since this study is being conducted at multiple sites, the National Health Research Ethics Committee of Nigeria has also reviewed it. If you have concerns about your rights as a research participant contact the Chairman at:

Department of Health Planning and Research,
Federal Ministry of Health,
Abuja
E-mail: chairman@nhrec.net.

What does my signature mean?

By signing or putting a thumbprint on the consent form you declare that you have been informed about the research study and voluntarily agree to participate in the survey. Signing or putting a thumbprint means that you understand the information in this consent form. You retain the right to withdraw from the study at any time. You do not waive any of your legal rights by signing this form.

Supplementary Information II: Consent Authorization

Consent to take part in the study of:

Antibodies Testing for SARS-CoV-2 Exposure in Akwa Ibom and Cross River States of Nigeria: a Seroepidemiologic Study to Guide Responses to COVID-19 Pandemic

Add your initials or thumbprint next to the statements below if you agree

I confirm that I have read and understood the information sheet dated [.....] explaining the above research project and I have had the opportunity to ask questions about the project.

I understand that my participation is voluntary and that I am free to withdraw at any time before or during the interviews without giving any reason and without there being any negative consequences. In addition, should I not wish to answer any particular question or questions, I am free to decline.

The contact number of the lead researcher is: 08032235333

I give permission for members of the research team to have access to my anonymized responses. I understand that my name will not be linked with the research materials, and I will not be identified or identifiable in the report or reports that result from the research.

I understand that my responses will be kept strictly confidential.

I agree for the data collected from me to be stored and used in relevant future research in an anonymized form. I understand that the results of the study will be published in academic journals.

I agree for the blood, saliva, or tissue collected from me to be stored and used in relevant future research in a de-identified form.

I agree to take part in the above research project and will inform the lead researcher should my contact details change.

Name of Participant

Signature /thumbprint

Date

For Illiterate Participants, to whom the consent was interpreted in a local language they understand

Name of Witness

Signature /thumbprint

Date

Supplementary Information III: Participants and Statistics

QUESTIONNAIRE

Hospital Number

Study Number

1. PERSONAL DATA

- i. Name.....(optional)
- ii. Age DOB
- iii. Sex Male Female
- iv. Social status: Married
Single
Student
Minor
Divorced
- v. Occupation (tick more than one)
- Civil servant
- Health Care Professional
- Student (tertiary Institution)
- Student (High School)
- Artisan
- Minor
- Clergy
- Other Professional Please specify
- vi. Your work exposes you to what number of people per day
- < 10
- > 10 but < 20
- >20 but < 40
- >40 but < 50
- .> 50 but < 60
- >100

2. LOCAL GOVERNMENT OF RESIDENCE

Address (where you have lived in the past 12 months) For participants in Akwa Ibom state	Address (where you have lived in the past 12 months) For participants in Cross River State
1. Oron <input type="checkbox"/>	1. Calabar Municipality <input type="checkbox"/>
2. Ibesikpo Asutan <input type="checkbox"/>	2. Abi <input type="checkbox"/>
3. Essien Udim <input type="checkbox"/>	3. Akamkpa <input type="checkbox"/>
4. Obot Akara <input type="checkbox"/>	4. Biase <input type="checkbox"/>
5. Etinan <input type="checkbox"/>	5. Yakuur <input type="checkbox"/>
6. Nsit Ubium <input type="checkbox"/>	6. Obudu <input type="checkbox"/>
7. Abak <input type="checkbox"/>	7. Ikom <input type="checkbox"/>
8. Ini <input type="checkbox"/>	8. Oban <input type="checkbox"/>
9. Ibiono Ibom <input type="checkbox"/>	9. Obanliku <input type="checkbox"/>
10. Ikot Ekpene <input type="checkbox"/>	10. Yala <input type="checkbox"/>
11. Eket <input type="checkbox"/>	11. Ogoja <input type="checkbox"/>
12. Okobo <input type="checkbox"/>	12. Bakassi <input type="checkbox"/>
13. Abak <input type="checkbox"/>	13. Obubra <input type="checkbox"/>
14. Ikono <input type="checkbox"/>	14. Akpabuyo <input type="checkbox"/>
15. Itu <input type="checkbox"/>	15. Calabar South <input type="checkbox"/>
16. Uyo <input type="checkbox"/>	16. Bekwarra <input type="checkbox"/>
17. Uruan <input type="checkbox"/>	17. Boki <input type="checkbox"/>
18. Ukanafun <input type="checkbox"/>	18. Etung <input type="checkbox"/>
19. Onna <input type="checkbox"/>	19. Odukpani <input type="checkbox"/>
20. Ikot Abasi <input type="checkbox"/>	
21. Ika <input type="checkbox"/>	
22. Ibeno <input type="checkbox"/>	
23. Eastern Obolo <input type="checkbox"/>	
24. Etim Ekpo <input type="checkbox"/>	
25. Mbo <input type="checkbox"/>	
26. Mkpat Enin <input type="checkbox"/>	
27. Nsit Atai <input type="checkbox"/>	
28. Oruk Anam <input type="checkbox"/>	
29. Nsit Ibom <input type="checkbox"/>	
30. Urue- Offong/Oruko <input type="checkbox"/>	

3. MEDICAL HISTORY

1. Have you been told that you have COVID-19 Yes No

2. When did you know that you have COVID-19
Feb-March April-May June-July

3. Have you been hospitalized before?
Yes No

4. If yes how many times and the best of your knowledge since the past 5 years
0 1 2 3 4 >5

5. Have you had any blood transfusion before? Yes No

6. If yes how many in the past 5 years? 1 2 3
4 >5

Last date of transfusion in the past 12 months if known

.....

7. Do you smoke cigarette Yes No Never Used to

8. Do you have any of these diseases (tick more than one)

Hypertension

Diabetes Mellitus

Asthma

Chronic obstructive pulmonary disease

Obesity

4. TRAVEL/ CONTACT HISTORY

1. Have you travelled out of Nigeria before? Yes No

2. If yes, How long ago? 2 Months 4 Months
6 Months

3. How long did you stay? < 2 weeks 2 weeks 4
weeks 6 Weeks > 6 weeks

4. Have you had any contact with someone who returned from
abroad Yes No

5. Did you have any contact with someone that later developed this
disease? Yes No I do not know

Supplementary Information IV: Participants and Statistics

INCLUSION CRITERIA

1. Persons who have no COVID-19 symptoms
2. Persons who present themselves to hospital with symptoms to COVID-19 infection.
3. Persons who have been tested positive for COVID-19, treated and discharged for the disease.
4. Any of the above who give consent to participate in the study

EXCLUSION CRITERIA

1. Patients who tested positive to SARS-CoV-2 less than one week before the study
2. Patients who decline consent to participate in the study

DATA HANDLING:

The questionnaires will be reviewed, and incomplete forms omitted. Data analysis will be done using the Statistical Package for Social Sciences (SPSS) IBM version 20.0. Continuous variables will be presented as means and standard deviation (SD) while categorical variables were presented as percentages. Continuous and categorical variables will be compared using Student's t-test and the chi-square test (or Fisher's exact test, when indicated). Results will be presented in tables and figures. Multivariate analysis will be done using logistic regression models to identify correlates of exposure to the virus among the participants. The level of statistical significance will be fixed at $P \leq 0.05$.

SAMPLE SIZE CALCULATION Sample size calculations are based on the primary outcome; number of symptomatic confirmed infections by SARS-CoV-2. Assuming the prevalence of COVID-19 is 50% error margin is 5% and non-response of 10%. Using the Cochran formulae for calculating sample size, formula gives us 422 with additional number to compensate for losses: 520 persons to be tested.

Supplementary Information V: Blood Collection and Testing Protocols

Blood Collection Protocol by Fingertick:

1. Use the middle or ring finger.
2. The puncture should be made slightly off center from the fleshy portion of the finger, near the side of the fingertip.
3. Disinfect thoroughly using an alcohol pad and let the puncture site air-dry.
4. Stick side of the finger with lancet.
5. Apply only light pressure on the fingertip until a blood drop appears. Don't press or milk the finger.
6. Discard lancet into a clearly labelled biohazard sharps container.
7. Wipe away the first two to three drops of blood with the alcohol pad and make sure there is a free blood flow.
8. Collect blood into capillary tube or sampler (~20-50 uL).

COVID-19 Serological Test Kits and Testing Protocol

1. Identify the sample number on the cassette.
2. Dispense the specimen into the sample well of the cassette.
3. Discard capillary sampler in a clearly labelled biohazard sharps container.
4. After the specimen has completely entered the sample well, add 2 to 3 drops of buffer solution. Make sure to test on a level surface at room temperature.
5. Set timer to 15 minutes.
6. Wash hands (keep one pair of gloves on) with 70% alcohol.
7. After 15 minutes, test results should be read by viewing the detection window.
8. Write all results on the laboratory worksheet and report form.
9. Dispose the cassettes and pipettes as biohazard materials.
10. Clean work surfaces and plastic materials (pipettors, pens, and timer) with alcohol at the end of the process.

Supplementary Information VI: Clinical Validation Data on Test Kits

Clinical Evaluation of Test Kits (see <https://www.healgen.com/if-respiratory-covid-19>)

Positive Percent Agreement (PPA): IgG 96.7%; IgM 86.7%; Overall 96.7%

Negative Percent Agreement (NPA): IgG 98.0%; IgM 99.0%; Overall 97.0%

Clinical Agreement with Characterized Samples

Sensitivity: IgG 96.7%; IgM 100%; Combined 100%

Specificity: IgG 97.5%; IgM 100%; Combined 97.5%

Specimen: Whole Blood, Serum, Plasma

Time to Results: 10 minutes. Shelf Life: 24 months from the date of manufacture

- Features of the Healgen Kits: Detection Window (IgM): 3-5 days after incubation
- Dual band results for simple interpretation
- Multivariable analysis of immunoglobulin IgG & IgM
- Room temperature storage or refrigerated (2-30°C / 36-86°F)
- Procedural internal control included
- Buffer included